Table 1.
Characteristics of the patients with cryptococcosis (N=129)
| Characteristic | N (%) |
|---|---|
| Age, median (IQR), year | 54 (44–60) |
| Male | 91/125 (73) |
| Type of transplant | |
| Liver | 30 (23) |
| Lung | 10 (8) |
| Kidney | 63 (49) |
| Heart | 11 (9) |
| Pancreas1 | 11 (9) |
| Combined2 | 4 (3) |
| Primary immunosuppressive agents | |
| Calcineurin inhibitors | 114 (88) |
| Tacrolimus | 95 (74) |
| Cyclosporine A | 19 (15) |
| Non-calcineurin inhibitor-based regimen3 | 15 (12) |
| T-cell antibody agent use4 | 7/79 (8) |
| Prednisone | 116 (90) |
| Median (IQR), mg | 10 (5–10) |
| Dose ≥10 mg/day | 64/116 (55) |
| Rejection | 30/128 (23) |
| Retransplantation | 16 (12) |
| Renal dysfunction (creatinine ≥2.0 mg/dl) | 35/107 (33) |
| CMV infection | 28/126 (22) |
| CMV disease | 15/122 (12) |
| Time to onset of cryptococcosis | |
| Median (IQR), month | 22 (8.9–50) |
| >12 months | 86 (67) |
| >24 months | 57 (44) |
| Symptoms | |
| Fever | 57/124 (46) |
| Abnormal mental status | 39/127 (31) |
| Site involved | |
| CNS | 80 (63) |
| Pulmonary | 71 (55) |
| Cutaneous | 23 (18) |
| Serum cryptococcal antigen | |
| Positive antigen | 80/98 (82) |
| Titer | |
| Median (IQR) | 64 (1–512) |
| >1:64 | 44/98 (45) |
| Fungemia | 31/122 (25) |
IQR, interquartile range; CMV, cytomegalovirus. Data are No. (%) of patients, unless otherwise indicated.
Denominators are shown when missing data exist.
1
Included 5 pancreas and 6 kidney-pancreas recipients.
2
Included 2 liver-kidney and 2 heart-kidney transplant recipients.
3
These patients received azathioprine (9), mycophenolate mofetil (3), mycophenolate mofetil and rapamycin (2), and prednisone (1) without a calcineurin-inhibitor agent.
4
Use within 6 months of onset of cryptococcosis.